High mobility group box-1 levels may be associated with disease activity of Behcet's disease

DİLARA DÖNMEZ GÜLER
AYŞE BAHAR KELEŞOĞLU DİNÇER
ZEYNEP CEREN KARAHAN
HASAN SELİM GÜLER
MÜÇTEBA ENES YAYLA

See next page for additional authors

Follow this and additional works at: https://journals.tubitak.gov.tr/medical

Part of the Medical Sciences Commons

Recommended Citation
GÜLER, DİLARA DÖNMEZ; DİNÇER, AYŞE BAHAR KELEŞOĞLU; KARAHAN, ZEYNEP CEREN; GÜLER, HASAN SELİM; YAYLA, MÜÇTEBA ENES; SEZER, SERDAR; GÜLÖKSÜZ, EMİNE GÖZDE AYDEMİR; OKATAN, İLYAS ERCAN; TORĞUTALP, MURAT; ERGÖLU, DİDEM ŞAHİN; YÜKSEL, MEHMET LEVENT; TURĞAY, TAHSİN MURAT; KINIKLI, GÜLAY; and ATEŞ, AŞKİN (2021) "High mobility group box-1 levels may be associated with disease activity of Behcet's disease," Turkish Journal of Medical Sciences: Vol. 51: No. 5, Article 58. https://doi.org/10.3906/sag-2101-116
Available at: https://journals.tubitak.gov.tr/medical/vol51/iss5/58

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more information, please contact academic.publications@tubitak.gov.tr.
High mobility group box-1 levels may be associated with disease activity of Behcet's disease

Authors
DİLARA DÖNMEZ GÜLER, AYŞE BAHAR KELEŞOĞLU DİNÇER, ZEYNEP CEREN KARAHAN, HASAN SELİM GÜLER, MÜÇTEBA ENES YAYLA, SERDAR SEZER, EMİNE GÖZDE AYDEMİR GÜLÖKSÜZ, İLYAS ERCAN OKATAN, MURAT TORĞUTALP, DİDEM ŞAHİN EROĞLU, MEHMET LEVENT YÜKSEL, TAHSİN MURAT TURĞAY, GÜLAY KINIKLI, and AŞKİN ATEŞ

This article is available in Turkish Journal of Medical Sciences: https://journals.tubitak.gov.tr/medical/vol51/iss5/58
High mobility group box- 1 levels may be associated with disease activity of Behcet’s disease

Dilara DÖNMEZ GÜLER1*, Ayşe Bahar KELEŞOĞLU DİNÇER2, Zeynep Ceren KARAHAN3, Hasan Selim GÜLER1, Müctebe Enes YAYLA4, Serdar SEZER5, Emine Gözde AYDEMİR GÜLOKSÜZ2, İlyas Erkan OKATAN2, Murat TORGUTALP5, Didem ŞAHİN EROĞLU2, Mehmet Levent YÜKSEL2, Tahsin Murat TURGAY2, Gülay KINIKLI2, Aşkın ATEŞ2

1Department of Internal Medical Sciences, Faculty of Medicine, Ankara University, Ankara, Turkey
2Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ankara University, Ankara, Turkey
3Department of Medical Microbiology, Faculty of Medicine, Ankara University, Ankara, Turkey

* Correspondence: dilara_gazi063@hotmail.com

1. Introduction
Behcet’s disease is a chronic inflammatory disease characterized by various systemic symptoms including skin lesions such as recurrent oral ulcers, genital ulcers, EN and papulopustular eruption (PPE), eye involvement such as uveitis and retinal vasculitis, musculoskeletal manifestations such as arthritis and arthralgia, and gastrointestinal, neurological, vascular, cardiac and pulmonary involvements [1]. Although its etiopathogenesis is not fully known, genetic factors and immune dysregulation are considered to play a significant role in the development of this disease [2].

High mobility group box- 1 (HMGB- 1) is a nonhistone protein with important biological activities both inside and outside the cell. HMGB- 1 is comprised of 215 amino acids, has a molecular weight of ~ 25 kDa, and includes two DNA-binding domains (A and B boxes) and a C-terminal acidic tail [3]. HMGB- 1 binds to different molecules through different receptors, leading to different metabolic functions. Receptor for Advance Glycation End Product (RAGE), a transmembrane protein belonging to the immunoglobulin (Ig) superfamily, is the first receptor described for HMGB- 1 [4]. Binding of HMGB- 1 with RAGE causes cell migration [5], whereas binding with Toll-like receptor 4 (TLR4) mediates inflammation through NF-κB activation and production of cytokines such as interleukin- 6 (IL- 6) and tumor necrosis factor-α (TNF-α) by macrophages [6-8], and binding to p53 causes gene transcription [9]. Extracellular HMGB- 1 arouses a potent inflammatory response stimulating the release of proinflammatory cytokines in neutrophils and macrophages [10]. Elevated serum HMGB- 1 level is reported in many autoimmune and inflammatory diseases [11–13].
Neutrophilic infiltration, endothelial cell swelling, necrosis and elevated serum levels of cytokines that prime the neutrophils were shown in the pathogenesis of BD [14]. These findings suggested BD to be a neutrophilic vasculitis [15]. Activated neutrophils in BD secrete cytokines that both prime themselves and stimulate T-helper-1 cells [14]. Emmi G and his colleagues demonstrated the important role of neutrophils in the development of thrombotic events in BD. They showed an increased leucocyte oxidative stress and radical oxygen species leading to posttranslational carbonylation of fibrinogen and reduced plasmin lysis, which were thought to play role in thrombus formation in BD [16]. On the other hand, intensive leucocytes recruitment is the most significant feature of HMGB-1 associated inflammation [17]. HMGB-1 can directly activate neutrophils to produce IL-1ß, IL-8 and TNF-α, which are one of the main cytokines of inflammation and related diseases [18]. With respect to this knowledge, we aimed to evaluate the role of HMGB-1 in BD and its association with clinical manifestations and disease activity.

2. Materials and methods

2.1. Study population

Ninety BD patients over the age of 18 who were diagnosed according to the 1990 International Study Group criteria for Behçet’s Disease [19] and followed between March 2018 and March 2019 at Ankara University Faculty of Medicine, Ibn-i Sina Hospital, Behçet’s Disease Multidisciplinary Diagnosis and Treatment Unit, and 50 age and sex compatible HC were recruited consecutively for the study. Patients with autoimmune or autoinflammatory diseases other than BD and patients with other comorbidities or infectious diseases during recruitment were excluded from the study.

2.2. Study design

Demographic data, clinical and treatment features of BD patients were obtained from patients at the time of study recruitment and also from the hospital records. Mucocutaneous manifestations included recurrent aphthous stomatitis, genital ulcers, EN, PPE and skin pathergy reaction. Papulopustular eruptions were defined as folliculitis or acne like lesions with sterile erythematous papules or pustules that are localized mostly on the lower extremities but also on upper extremities, trunk, face and neck [20, 21]. Mucocutaneous involvement was assessed by physical examination at the time of recruitment. Joint involvement was described as synovial inflammation which could not be otherwise explained by any other inflammatory arthritis and was diagnosed by physical examination and imaging studies as conventional radiography, ultrasound and/or magnetic resonance imaging (MRI). Ocular involvement included inflammation of uvea and retina (namely, uveitis and retinits, respectively). Uveitis was classified as isolated anterior uveitis, posterior uveitis and panuveitis according to ophthalmologist’s examination. Vascular involvement included both arterial and venous involvements. Pulmonary and/or peripheral artery aneurisms and/or thrombosis were classified as arterial involvement; whereas deep venous thromboses were classified as venous involvement. The diagnosis of vascular involvement was confirmed by arterial and/or venous doppler ultrasonography, computed tomography, MRI, echocardiography and/or scintigraphy. Gastrointestinal system (GIS) involvement was defined as presence of punched-out or aphthous ulcers in endoscopic studies in patients with gastrointestinal symptoms that could not be explained by other diseases. Central nervous system (CNS) involvement was defined as presence of parenchymal disease and/or cerebral venous sinus thrombosis in neuroimaging studies in patients with neurological symptoms that could not be explained by another systemic/neurological disease or usage of any drug. Major organ involvement (MOI) was defined as the presence of at least one of the eye, vascular, CNS or GIS involvements as described previously.

The disease activity of BD was evaluated at hospital visit during recruitment. In order to evaluate disease activity; two measures were used. One of the measures used was Behcet Syndrome Activity Score (BSAS) which is a ten-question patient derived assessment tool. It scores the degree of discomfort caused by the current clinical findings over the last four weeks of patient assessment by the patient visual analogue scales [22, 23]. It is scored between 0 - 100. The other activity index used was Behcet Disease Current Activity Form (BDCAF) which is a commonly used index that scores the absence or presence of clinical manifestations over the last four weeks prior to patient hospital visit [23, 24]. The total score is 12. Patients with a score of ≥ 2 were accepted as “active” [24, 25]. Both indices had been translated to Turkish correctly and are commonly used in daily practice [23].

Peripheral blood samples were drawn from BD patients for routine evaluation of Erythrocyte Sedimentation Rate (ESR) (0 - 20 mm/h), C-Reactive protein (CRP) (0 - 5 mg/L) and complete blood count (CBC).

2.3. Enzyme-linked immunosorbent assay (ELISA)

Peripheral venous blood samples were collected from BD patients and HC by using proper tubes to determine their serum HMGB-1 levels, and then the samples were centrifuged at 3000 rpm for 15 minutes and stored at -80 °C. The samples were processed using ELISA kits (LifeSpan BioSciences, Inc., Seattle, USA) (Catalog No: LS-F11641) at Ankara University, Faculty of Medicine, Ibn-i Sina Hospital Microbiology Laboratory.
3.1. Demographic and clinical features
The demographic and clinical features of BD patients were summarized in Table 1. Median serum HMGB-1 levels were significantly higher in BD patients (43.26 (0–221.33) pg/mL) in comparison to HC (16.73 (0–41.95) pg/mL) (p < 0.001).

In four patients, colchicine was ceased due to side effects. Azathioprin was the mostly commonly used (22.22%) disease modifying antirheumatic drug. In one patient, cyclophosphamide was used due to the acute thrombosis of superior vena-cava. Adalimumab was the only preferred biological disease-modifying antirheumatic drug in our patients, which was used for recurrent panuveitis and refractory gastrointestinal involvement.

3.2. Association of serum HMGB-1 level with BD manifestations
We observed that in patients who had genital ulcers and EN-like lesions in the past four weeks prior to recruitment had significantly higher levels of HMGB-1 (p = 0.041 and p < 0.0001) (Table 2).

No statistically significant difference was found between patients with and without vascular, ocular or MOI involvements (p = 0.552, p = 0.329 and p = 0.212, respectively) (Table 3).

3.3. Association of serum HMGB-1 level with disease activity scores
There was weak but positive correlation between serum HMGB-1 levels, BSAS and BDCAF scores (r = 0.24, p = 0.022 and r = 0.24, p = 0.026, respectively). Serum HMGB-1 level of active BD patients (n = 52) was significantly higher than inactive patients (n = 38) (median 45.17 and 27.97 pg/mL respectively; p = 0.035).

4. Discussion
HMGB-1 is a nonhistone protein that can be found both inside and outside the cell and has different functions by its location [26]. It regulates transcription and autophagy when it is bound with DNA within the cell [26]. During cell activation, death or damage; it is released outside of the cell, acting as an alarmin or Damage Associated Molecular Pattern (DAMP) to activate the innate immune system [27]. Due to its interaction with chemokines, cytokines and Pathogen Associated Molecular Pattern (PAMP), HMGB-1 is considered to play a role in the pathogenesis of inflammatory and autoimmune diseases [28].

In the literature, there are studies showing that serum HMGB-1 levels are higher in patients with chronic systemic inflammatory diseases when compared to HC [12, 29–31]. Taniguchi et al. [32] measured the HMGB-1 concentrations in sera and synovial fluids of 30 rheumatoid arthritis (RA) and 30 osteoarthritis patients and found statistically significant higher concentrations of HMGB-1 in both sera and synovial fluids of RA patients. Goldstein et al. [29] also showed that serum HMGB-1 levels were higher in RA patients compared to HC and that it correlated significantly with disease activity score of 28 joints. In the study with 147 ankylosing spondylitis (AS) patients, serum HMGB-1 level of AS patients was significantly higher than in HC and it was correlated positively with AS disease activity indices such as Bath Ankylosing Spondylitis Disease activity index (BASDAI), Bath Ankylosing spondylitis Functional index (BASFI), Ankylosing spondylitis disease activity score-ESR (ASDAS-ESR), ASDAS-CRP, ESR, and CRP [31]. A study conducted with 169 Granulomatosis with polyangiitis (GPA) patients in Germany [33] demonstrated higher serum HMGB-1 levels in GPA in comparison to HC and also in this study, higher serum HMGB-1 levels were found in patients with more dominant granulomatous manifestations. To the best of our knowledge, there are only two studies in the literature evaluating the serum HMGB-1 levels in BD patients.

In our study, serum HMGB-1 level was found to be significantly higher in BD patients than in HC. The results of the other two studies evaluating the serum HMGB-1 levels in BD patients support our results [24,34]. Hyperfunction of neutrophils, vascular injury and autoimmune responses
are involved in the pathogenesis of BD [14]. Innate immune
system plays a critical role in the initiation and aggregation
of inflammation in BD [34]. It was demonstrated that
cells and migrate to inflamed areas, which showed the
central role of leucocytes in the pathogenesis of BD. In
BD, there is not only enhanced neutrophil chemotaxis,
but also the neutrophils are overreactive, which was

Table 1. Demographic, clinical characteristics since disease onset and laboratory findings of BD patients.

|                          | Behcet’s disease | Healthy control | p value  |
|--------------------------|------------------|-----------------|----------|
| Age, years, mean (± SD)  | 42.16 ± 9.69     | 39.00 ± 10.65   | 0.128    |
| Sex, women, n (%)        | 51 (56.70)       | 32 (64.00)      | 0.401    |
| Disease duration (years), median (min - max) | 10 (1–37) |                      |          |
| Clinical manifestations, n (%) |                      |                  |          |
| Oral ulcers              | 90 (100.00)      |                 |          |
| Genital ulcers           | 68 (75.55)       |                 |          |
| Erythema nodosum like lesions | 52 (57.77) |               |          |
| Papulopustuler eruption  | 59 (65.55)       |                 |          |
| Pathergy positivity      | 37 (41.11)       |                 |          |
| Uveitis                  | 27 (30.00)       |                 |          |
| Retinal vasculitis       | 2 (2.22)         |                 |          |
| CNS involvement          | 7 (7.77)         |                 |          |
| GIS involvement          | 2 (2.22)         |                 |          |
| Arthralgia               | 75 (83.33)       |                 |          |
| Arthritis                | 15 (16.66)       |                 |          |
| Arterial involvement     | 3 (3.33)         |                 |          |
| Venous involvement       | 25 (27.77)       |                 |          |
| Major organ involvement  | 47 (52.22)       |                 |          |
| Treatment, n (%)         |                  |                 |          |
| Colchicine               | 86 (95.55)       |                 |          |
| Azathioprine             | 20 (22.22)       |                 |          |
| Mycophenolate mofetil    | 1 (1.11)         |                 |          |
| Methotrextate            | 1 (1.11)         |                 |          |
| Cyclophosphamide         | 1 (1.11)         |                 |          |
| Sulfasalazine            | 2 (2.22)         |                 |          |
| Adalimumab               | 2 (2.22)         |                 |          |
| Laboratory findings, median (min - max) |          |                  |          |
| Serum HMGB-1 level (pg/mL) | 43.26 (0 –221.33) | 16.73 (0– 41.95) | < 0.001* |
| ESR (mm/h)               | 9 (1 – 48)       |                 |          |
| CRP (mg/L)               | 2.25 (0.30–169.00) |               |          |
| MPV (fL)                 | 10.50 (8.30– 12.50) |             |          |
| Neutrophil/lymphocyte ratio | 1.90 (0.67– 6.56) |            |          |
| Platelet/lymphocyte ratio | 122.05 (50.7–373.8) |            |          |
| Activity Scores, median (min - max) |          |                  |          |
| BSAS                     | 10 (0–54)        |                 |          |
| BDCAF                    | 2 (0–6)          |                 |          |

T test was used for parametric data.  
Mann–Whitney U test was used for nonparametric data.
proved by the increased production of superoxide and lysosomal enzymes. Alarmins are released as signaling molecules after trauma, infection or injury [35]. When the pattern recognition receptors of alarmins bind with pathogen associated molecular pattern molecules, the immune system is activated, proinflammatory cytokines are released and inflammation is triggered. HMGB-1 acts as an alarmin in several tissues and activates the innate immune system [36]. As a result, serum HMGB-1 level is considered to increase in BD as HMGB-1 is a strong stimulator of the innate immune system [34]. De Souza et al. [24] found higher serum HMGB-1 levels in the BD group (n = 26) than in the HC group (n = 20), but they did not show a relationship between BDCAF scores and serum HMGB-1 levels (p = 0.339). In our study, though, we used both BSAS and BDCAF to evaluate disease activity which are reliable, validated and frequently used indices, and we found statistically significant but weakly positive correlations between these scores and serum HMGB-1 levels. The higher number of patients in our study might have led to a significant relationship between activity scores and serum HMGB-1 level. In addition, de Souza et al. used only BDCAF, but we used not only BDCAF but also BSAS, which is a newer activity measure of BD. To the best of our knowledge, there is no study in the literature that has evaluated the relationship between BSAS and HMGB-1 level. As we found significantly positive correlations in both indices, this may indicate our results being more accurate and reliable.

In some studies, patients with BDCAF score ≥ 2 were considered as “active” [24,25]. We also considered patients with BDCAF ≥ 2 as active in our study and examined the serum HMGB-1 levels of active (BDCAF ≥ 2) and inactive (BDCAF < 2) patients. We found significantly higher HMGB-1 levels in active patients.

### Table 2. Comparison of serum HMGB-1 levels in BD patients with and without clinical involvement in the last four weeks.

| Current clinical findings | HMGB-1 level median (min - max) | p value |
|---------------------------|---------------------------------|---------|
| Oral ulcer               |                                 |         |
| (+) (n = 60)             | 44.03 (0–221.33)                | 0.218   |
| (-) (n = 30)             | 39.11 (0–103.91)                |         |
| Genital ulcer            |                                 |         |
| (+) (n = 7)              | 47.11 (43.26–221.33)            | 0.041’  |
| (-) (n = 83)             | 42.50 (0–103.91)                |         |
| EN-like lesion           |                                 |         |
| (+) (n = 14)             | 51.83 (27.90–75.25)             | < 0.001’|
| (-) (n = 76)             | 39.85 (0–221.33)                |         |
| Papulopustular eruption  |                                 |         |
| (+) (n = 26)             | 45.17 (5.46–62.42)              | 0.216   |
| (-) (n = 64)             | 41.36 (0–221.33)                |         |
| Arthralgia/arthritis     |                                 |         |
| (+) (n = 57)             | 43.26 (0–221.33)                | 0.723   |
| (-) (n = 33)             | 42.88 (0–103.91)                |         |
| Major organ involvement  |                                 |         |
| (+) (n = 4)              | 44.3. (35.05–47.89)             | 0.314   |
| (-) (n = 86)             | 43.26 (0–221.33)                |         |

(+): present; (-): absent

Mann–Whitney U test was used.
and, even though, higher extracellular HMGB-1 expression in active patients (n = 25) compared to inactive patients (n = 17) was shown, it was not statistically significant. This study has defined active disease as follows: having at least three of the following symptoms due to the worsening of clinical findings during the study: oral ulcer or stomatitis, genital ulcer, anterior iridocyclitis, posterior vasculitis or panuveitis, cutaneous symptoms, or pathergy positivity [34]. In our study, the correlation of serum HMGB-1 level with other inflammatory markers such as ESR and CRP were also examined, but no significant correlation was found. Similarly, Ahn et al. [34] found no significant correlation between serum HMGB-1 level, ESR, CRP and leukocyte count.

In our study, we also evaluated the association between serum HMGB-1 level and clinical findings of BD patients. While mucocutaneous and joint involvements were evaluated according to their presence in the last four weeks, MOI (i.e. the presence of at least one involvement of the eye, vascular, CNS, and GIS) was evaluated as both by their presence in the last four weeks of recruitment and since the onset of the disease as the number of patients with current MOI was small in our study. However, we found no association between serum HMGB-1 level and the presence of vascular, ocular and MOI as indicators of disease severity. On the other hand, significantly higher serum HMGB-1 levels were found only in patients with genital ulcer and EN-like lesions. De Souza et al. [24] found no significant correlation between serum HMGB-1 levels and both mucocutaneous and MOI (i.e., eye, neuro- and vasculo- Behcet's diseases). Ahn et al. [34] showed statistically significant higher extracellular HMGB-1 expression in patients with intestinal involvement than in those without intestinal involvement but could not found any association between other clinical findings. RAGE, a transmembrane protein belonging to the Ig superfamily, was the first receptor described for HMGB-1 [4]. RAGE is expressed at low levels in normal tissues and vasculature but is upregulated at sites where its ligands accumulate causing neutrophil chemotaxis. Binding of RAGE by its ligands increases the permeability of the vascular endothelium and enhances the expression of adhesion molecules such as VCAM-1 and proinflammatory cytokines like procoagulant tissue factor and or interleukin-6 [37]. This is why it is thought that HMGB-1 plays a role in vascular involvement in BD [33]. Orogenital ulcerations and EN-like lesions are examples of direct injury to vessel wall in BD [34]. In the study of Demirkesen et al. [38], a neutrophilic vasculitis was shown in almost half of the nodular lesions of BD, and predominantly neutrophil infiltration was statistically important parameter proving the BD lesion. This may explain the high serum HMGB-1 levels in our patients with genital ulcers and EN-like lesions. In this study, the number of patients with MOI in the last four weeks of recruitment was small, it might have affected our results. Therefore, the correlation between MOI and serum HMGB-1 levels should be examined in further studies conducted with larger number of patients.

This study has some limitations. First, this was a cross-sectional study, which included only BD and HC. Association of serum HMGB-1 level with BD could be interpreted more precisely if other inflammatory diseases were included as control group. Even if we found a correlation between disease activity indices and serum HMGB-1 level, a prospective study should be designed to evaluate the change in serum HMGB-1 level after appropriate disease control in active patients. Secondly, as the number of patients with current MOI was small, examining serum HMGB-1 level with larger number of active patients may be useful in clarifying the role of HMGB-1 in BD pathogenesis. In addition, examining HMGB-1 levels at the tissue level may also be useful in explaining the correlation between HMGB-1 and BD. For this purpose, it can be suggested to study HMGB-1 levels, in biopsy samples from active mucocutaneous lesions and synovial fluid aspirates in patients with synovial inflammation secondary to BD. Lastly, in order to investigate the correlation of HMGB-1 with other proinflammatory cytokines involved in BD pathogenesis, these cytokine levels in the serum can also be examined simultaneously.

5. Conclusion

In this study, higher serum HMGB-1 level was found in BD patients than in HC. Unlike other studies, this study also showed that serum HMGB-1 levels in BD patients were positively correlated with BSAS and BDCAF scores. These results suggest that HMGB-1 may have a role in BD.

|                  | HMGB-1 level median (min - max) | p value |
|------------------|---------------------------------|---------|
| Eye involvement  |                                 |         |
| (+) (n = 28)     | 45.18 (5.46–58.29)              | 0.329   |
| (-) (n = 62)     | 41.37 (0–221.33)                |         |
| Vascular involvement |                               |         |
| (+) (n = 27)     | 45.56 (5.46–103.91)             | 0.552   |
| (-) (n = 63)     | 42.5 (0–221.33)                 |         |
| Major organ involvement |                           |         |
| (+) (n = 47)     | 44.79 (5.46–103.91)             | 0.212   |
| (-) (n = 43)     | 37.15 (0–221.33)                |         |

Mann–Whitney U test was used.
development and can be used to monitor disease activity. These results should be supported by further studies that include higher number of patients and patients with other inflammatory diseases in order to clarify the association between HMGB-1 and BD.

Acknowledgements/disclaimers/conflict of interest
We would like to thank everyone who contributed to this project and Scientific Research Projects Unit of Ankara University for their financial support.

Funding
Our study was funded by the Scientific Research Projects Unit of Ankara University (Project number: 18L0230003).

Informed consent
The study was conducted according to the Declaration of Helsinki, and written consent was received from the patients. The study protocol was approved by Ankara University Faculty of Medicine Ethics Board (Approval Number: 12-724-17).

References
1. Davatchi F. Behçet’s disease. International journal of rheumatic diseases 2018; 21 (12): 2057. doi: 10.1111/1756-185X.13465
2. de Chambrun MP, Wechsler B, Geri G, Cacoub P, Saadoun D. New insights into the pathogenesis of Behcet's disease. Autoimmunity reviews 2012; 11 (10): 687-98. doi: 10.1016/j.autrev.2011.11.026
3. Lee S, Kwak MS, Kim S, Shin J-S. The role of high mobility group box 1 in innate immunity. Yonsei medical journal 2014; 55 (5): 1165-76. doi: 10.3349/yjm.2014.55.5.1165
4. Pillweger C, Holdenrieder S. Circulating HMGB1 and RAGE as clinical biomarkers in malignant and autoimmune diseases. Diagnostics 2015; 5 (2): 219-53. doi: 10.3390/diagnostics5020219
5. Huttunen HJ, Fages C, Kuja-Panula J, Ridley AJ, Rauvala H. Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer research 2002; 62 (16): 4805-11. doi: Published August 2002
6. Park JS, Svetkaukaitė D, He Q, Kim JY, Strassheim D et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. The Journal of biological chemistry 2004; 279 (9): 7370-7. doi: 10.1074/jbc.M306793200
7. Park JS, Gamboni-Robertson F, He Q, Svetkaukaitė D, Kim JY et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. American journal of physiology Cell physiology 2006; 290 (3): C917-24. doi: 10.1152/ajpcell.00401.2005
8. Ivanov S, Dragoi AM, Wang X, Dallacosta C, Luiten J et al. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 2007; 110 (6): 1970-81. doi: 10.1182/blood-2006-09-044776
9. Kang R, Chen R, Zhang Q, Hou W, Wu S et al. HMGB1 in health and disease. Molecular aspects of medicine 2014; 40:1-116. doi: 10.1016/j.mam.2014.05.001
10. Andersson U, Wang H, Palmblad K, Aveberger A-C, Bloom O et al. High mobility group 1 protein (HMGB-1) stimulates proinflammatory cytokine synthesis in human monocytes. Journal of Experimental Medicine 2000; 192 (4): 565-70. doi: 10.1084/jem.192.4.565
11. Hamada T, Torikai M, Kuwazuru A, Tanaka M, Horai N et al. Extracellular high mobility group box chromosomal protein 1 is a coupling factor for hypoxia and inflammation in arthritis. Arthritis & Rheumatism 2008; 58 (9): 2675-85. doi: 10.1002/art.23729
12. Ma C, Y, Jiao Y-L, Zhang J, Yang Q-r, Zhang Z-f et al. Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-alpha and TNF-alpha in systemic lupus erythematosus. Rheumatology international 2012; 32 (2): 395-402. doi: 10.1007/s00296-010-1636-6
13. Ulfgren AK, Grundman C, Borg K, Alexanderson H, Andersson U et al. Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. Arthritis & Rheumatism 2004; 50 (5): 1586-94. doi: 10.1002/art.20220
14. Mendoza-Pinto C, Garcia-Carrasco M, Jiménez-Hernández M, Hernández CJ, Riebeling-Navarro C et al. Etiopathogenesis of Behcet's disease. Autoimmunity reviews 2010; 9 (4): 241-5. doi: 10.1016/j.autrev.2009.10.005
15. Ling E, Shubinsky G, Press J. Increased proportion of CD3+ CD4− CD8− double-negative T cells in peripheral blood of children with Behcet's disease. Autoimmunity reviews 2007; 6 (4): 237-40. doi: 10.1016/j.autrev.2006.08.008
16. Emmi G, Bettiol A, Silvestri E, Di Scala G, Becatti M et al. Vascular Behçet's syndrome: an update. Internal and Emergency Medicine 2019; 14 (5): 645-52. doi: 10.1007/s11739-018-1991-y
17. Dumitriu IE, Baruah P, Manfredi AA, Bianchi ME, Rovere-Querini P. HMGB1: guiding immunity from within. Trends in immunology 2005; 26 (7): 381-7. doi: 10.1016/j.it.2005.04.009
18. Park JS, Arcaroli J, Yang H, Wang H et al. Activation of gene expression in human neutrophils by high mobility group box 1 protein. American Journal of Physiology-Cell Physiology 2003; 284 (4): C870-C9. doi: 10.1152/ajpcell.00322.2002
19. ISGfBs D. Criteria for diagnosis of Behçet’s disease. International Study Group for Behcet’s Disease. Lancet 1990; 335: 1078-80.
20. Alpsoy E. Behcet's disease: a comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions. The Journal of dermatology 2016; 43 (6): 620-32. doi: 10.1111/1346-8138.13381

21. Boyvat A, Heper AO, Koçyiğit P, Erekul S, Gürgey E. Can specific vessel-based papulopustular lesions of Behçet's disease be differentiated from nonspecific follicular-based lesions clinically? International journal of dermatology 2006; 45 (7): 814-8. doi: 10.1111/j.1365-4632.2006.02797.x

22. Türsen Ü. Behçet Hastalığında Aktivite Belirteçleri. Archives of the Turkish Dermatology & Venerology/Turkderm 2009; 43.

23. Yilmaz S, Simsek I, Cinar M, Erdem H, Kose O et al. Patient-driven assessment of disease activity in Behcet's syndrome: cross-cultural adaptation, reliability and validity of the Turkish version of the Behcet’s Syndrome Activity Score. Clin Exp Rheumatol 2013; 31 (3 Suppl 77): 77-83.

24. de Souza AW, Félix Perazzio S, de França NR, Andrade LEC, Bijl M et al. High mobility group box 1 serum levels are increased in Behcet's disease, but not associated with disease activity or disease manifestations. Rheumatology 2015; 54 (12): 2151-5. doi: 10.1093/rheumatology/kev202

25. Ha YJ, Park JS, Kang Mi, Lee SK, Park YB et al. Increased serum interleukin-32 levels in patients with Behçet's disease. International journal of rheumatic diseases 2018; 21 (12): 2167-74. doi: 10.1111/1756-185X.13072

26. Magna M, Pisetsky DS. The role of HMGB1 in the pathogenesis of inflammatory and autoimmune diseases. Molecular medicine 2014; 20 (1): 138-46. doi: 10.2119/molmed.2013.00164

27. Harris HE, Andersson U, Pisetsky DS. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nature Reviews Rheumatology 2012; 8 (4): 195. doi: 10.1038/nrrheum.2011.222

28. Andersson U, Harris HE. The role of HMGB1 in the pathogenesis of rheumatic disease. Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms 2010; 1799 (1-2): 141-8. doi: 10.1016/j.bbagen.2009.11.003

29. Goldstein RS, Bruchfeld A, Yang L, Qureshi AR, Gallowitsch-Puerta M et al. Cholinergic anti-inflammatory pathway activity and High Mobility Group Box-1 (HMGB1) serum levels in patients with rheumatoid arthritis. Molecular medicine 2007; 13 (3-4): 210-5. doi: 10.2119/2006–00108.Goldstein

30. Dupire G, Nicaise C, Gangji V, Soyfoo MS. Increased serum levels of high-mobility group box 1 (HMGB1) in primary Sjögren’s syndrome. Scandinavian journal of rheumatology 2012; 41 (2): 120-3. doi: 10.1130/03009742.2011.633099

31. Wang C, Miao Y, Wu X, Huang Y, Sun M et al. Serum HMGB1 serves as a novel laboratory indicator reflecting disease activity and treatment response in ankylosing spondylitis patients. Journal of immunology research 2016; 2016. doi: 10.1155/2016/6537248

32. Taniguchi N, Kawahara KI, Yone K, Hashiguchi T, Yamakuchi M et al. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology 2003; 48 (4): 971-81. doi: 10.1002/art.10859

33. Henes F, Chen Y, Bley T, Fabel M, Both M et al. Correlation of serum level of high mobility group box 1 with the burden of granulomatous inflammation in granulomatosis with polyangiitis (Wegener’s). Annals of the rheumatic diseases 2011; 70 (11): 1926-9. doi: 10.1136/ard.2010.146456

34. Ahn JK, Cha H-S, Bae E-K, Lee J, Koh E-M. Extracellular high-mobility group box 1 is increased in patients with Behcet's disease with intestinal involvement. Journal of Korean medical science 2011; 26 (5): 697-700. doi: 10.3346/jkms.2011.26.5.697

35. De Martinis M, Sirufo MM, Ginaldi L. Osteoporosis: Current and emerging therapies targeted to immunological checkpoints. Current medicinal chemistry 2019. doi: 10.2174/0929867326666190730113123

36. De Martinis M, Ginaldi L, Sirufo MM, Pioggia G, Calapai G et al. Alarmins in Osteoporosis, RAGE, IL-1, and IL-33 Pathways: A Literature Review. Medicina 2020; 56 (3): 138. doi: 10.3390/medicina56030138

37. Chavakis T, Bierhaus A, Al-Fakhri N, Schneider D, Witte S et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte Integrins-a novel pathway for inflammatory cell recruitment. The Journal of experimental medicine 2003; 198 (10): 1507-15. doi: 10.1084/jem.20030800

38. Demirkesen C, Türzünner N, Mat C, Senocak M, Büyükabbrani N et al. Clinopathologic evaluation of nodular cutaneous lesions of Behçet syndrome. American journal of clinical pathology 2001; 116 (3): 341-6. doi: 10.1309/GCTH-0060-55K8-XCTT